Osteoradionecrosis of the Mandibula in Patients Treated with Different Fractionations

Strahlentherapie und Onkologie

Volumn 180, Issue 4, 2004, Pages 233-240

  Studer, Gabriela ^a   Grätz, Klaus W ^a   Glanzmann, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acceleration; Fractionation; Head neck irradiation; Hyperfractionation; Late effects; Mandibula; Osteoradionecrosis

Indexed keywords

ARTICLE; BONE NECROSIS; DOSE CALCULATION; FRACTIONATION; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MANDIBLE; MANDIBLE RESECTION; RADIATION DOSE; RADIATION HAZARD;

CHI-SQUARE DISTRIBUTION; DENTAL CARE; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MANDIBLE; MANDIBULAR DISEASES; OSTEORADIONECROSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 1842765543     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1171-z     Document Type: Article

References (33)

1. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-8.
2. Bieri S, Bentzen SM, Huguenin P, et al. Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies. Strahlenther Onkol 2003;179:390-5.
3. Chong J, Hinckley LK, Ginsberg LE. Masticator space abnormalities associated with mandibular osteoradionecrosis: MR and CT findings in five patients. AJNR Am J Neuroradiol 2000;21:175-8.
4. Cox JD, Pajak TF, Marcial VA, et al. ASTRO plenary. Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from the RTOG protocol 83-13. Int J Radiat Oncol Biol Phys 1991;20:1191-5.
5. Daly T. Dental care in the irradiated patient. In: Fletcher GH, eds. Textbook of radiotherapy. Philadelphia: Lea & Febiger, 1980:229-36.
6. Dische S, Saunders M, Barett A, et al. Randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
7. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
8. Fu KK, Pajak PF, Marcial VA, et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 1995;32:577-88.
9. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 90-03. Int J Radiat Oncol Biol Phys 2000;48:7-16.
10. Glanzmann C. Langzeit-Resultate nach postoperativer und primärer Radiotherapie von Karzinomen der Kopfspeicheldrüsen: Bedeutung von Dosis und Zielvolumen. Strahlenther Onkol 1990;166:183-9.
11. Glanzmann C, Grätz KW. Radionecrosis of the mandible: a retrospective analysis of the incidence and risk factors. Radiother Oncol 1995;36:94-100.
12. Grotz KA. Gemeinsame Stellungnahme der Deutschen Gesellschaft für Zahn-, Mund- und Kieferheilkunde; Deutschen Gesellschaft für Radioonkologie, Medizinische Physik und Strahlenbiologie; Abstimmung mit dem Vorstand der Deutschen Gesellschaft für Zahnerhaltungskunde. Dental care for patients with antineoplastic radiotherapy of the head and neck. Strahlenther Onkol 2003;179:275-8.
13. Gwozdz JT, Morrison WH, Garden AS, et al. Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. Int J Radiat Oncol Biol Phys 1997;39:127-35.
14. Hartmann A, Almeling M, Carl UM. Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects. Strahlenther Onkol 1996;172:641-8.
15. Hartmann KA, Almeling M, Carl UM, et al. Comment. Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects. Clinical experiences are decisive! Strahlenther Onkol 1998;174:221-2.
16. Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev 2002;28:65-74.
17. Kuechler A, Dreidax M, Pigorsch SU, et al. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. Strahlenther Onkol 2003;179:493-8.
18. Mak AC, Morrison WH, Garden SA, et al. Base-of-tongue carcinoma: treatment results using concomitant boost radiotherapy. Int J Radiat Oncol Biol Phys 1995;33:289-96.
19. Mendenhall WM, Amdur RJ, Stringer SP, et al. Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery? J Clin Oncol 2000;18:2219-25.
20. Morrish RBJ, Chan E, Silverman SJ. Osteonecrosis in patients irradiated for head and neck carcinoma. Cancer 1981;47:1980-3.
21. Niewald M, Barbie O, Schnabel K, et al. Risk factors and dose-effect relationship for osteonecrosis after hyperfractionated and conventionally fractionated radiotherapy for oral cancer. Br J Radiol 1996;69:847-51.
22. Parsons JT, Mendenhall WM, Cassisi NJ, et al. Hyperfractionation for head and neck cancer. Int J Radiat Oncol Biol Phys 1988;14:649-58.
23. Perier M, Moeller P. Osteoradionecrosis. A review of the literature. Schweiz Monatsschr Zahnmed 1994;104:271-7.
24. Plafki C, Carl UM, Glag M, et al. The treatment of late radiation effects with hyperbaric oxygenation (HBO). Strahlenther Onkol 1998;174:Suppl 3:66-8.
25. Remmler D, Medina JE, Byers RM, et al. Treatment of choice for squamous carcinoma of the tonsillar fossa. Head Neck Surg 1985;7:206-11.
26. Rhomberg W, Böhler F-K, Novak H, et al. A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlenther Onkol 2003;179:249-53.
27. Schulz-Ertner D, Didinger B, Nikoghosyan A, et al. Optimization of radiation therapy for locally advanced adenoid cystic carcinomas with infiltration of the skull base using photon intensity-modulated radiation therapy (IMRT) and a carbon ion boost. Strahlenther Onkol 2003;179:345-51.
28. Thiel HJ. Hyperbaric oxygenation in osteoradionecrosis of the mandible. Strahlenther Onkol 1994;170:614-5.
29. Thilmann C, Adamietz IA, Bottcher HD. Which action mechanisms are secured in the treatment of radiogenic side effects by hyperbaric oxygenation? Comment on the article by A. Hartmann, M. Almeling, U.M. Carl: Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects, Strahlenther Onkol 1996;172:641-8 (No. 12). Strahlenther Onkol 1998;174:221.
30. Thilmann C, Adamietz IA, Bottcher HD. Which action mechanisms are secured in the treatment of radiogenic side effects by hyperbaric oxygenation? Comment on the article by A. Hartmann, M. Almeling, U.M. Carl: Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects, Strahlenther Onkol 1996;172:641-8 (No. 12). Strahlenther Onkol 1998;174:221.
31. Thorn JJ, Hansen HS, Specht L, et al. Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg 2000;58:1088-93.
32. Toljanic JA, Ali M, Haraf DJ, et al. Osteoradionecrosis of the jaws as a risk factor in radiotherapy: a report of an eight year retrospective review. Oncol Rep 1998;5:345-9.
33. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of postoperative radiochemotherapy ± amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 2003;179:385-9.